Mao Ding
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mao Ding has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Shudong Wang
College of Computer Science and Technology, China University of Petroleum, Qingdao 266580, China
4 shared publications- Tao Song
Qingdao Institute of Software, College of Computer Science and Technology, China University of Petroleum (East China), Qingdao 266580, China
3 shared publications Alfonso Rodriguez-Paton
Department of Artificial Intelligence, Faculty of Computer Science, Polytechnical University of Madrid, Campus de Montegancedo, Boadilla del Monte 28660, Madrid, Spain
2 shared publications- Xun Wang
China University of Petroleum East China
2 shared publications Yue Zhong
College of Computer Science and Technology, China University of Petroleum (East China), Qingdao, China
2 shared publicationsZhenzhen Du
College of Computer Science and Technology, China University of Petroleum, Qingdao, China
2 shared publications
Latest Publications
- 30 December 2021
- Published by Wiley in Molecular Informatics
- Vol. 41 (5) , 2100200
Network‐Based Approaches for Drug Repositioning
With deep learning creeping up into the ranks of big data, new models based on deep learning and massive data have made great leaps forward rapidly in the field of drug repositioning. However, there is no relevant review to summarize the transformations and development process of models and their data in the field of drug repositioning. Among all the computational methods, network‐based methods play an extraordinary role. In view of these circumstances, understanding and comparing existing network‐based computational methods applied in drug repositioning will help us recognize the cutting‐edge technologies and offer valuable information for relevant researchers. Therefore, in this review, we present an interpretation of the series of important network‐based methods applied in drug repositioning, together with their comparisons and development process.
- 30 December 2021
- Published by Wiley in Molecular Informatics
- Vol. 41 (5) , 2100200
Network‐Based Approaches for Drug Repositioning
With deep learning creeping up into the ranks of big data, new models based on deep learning and massive data have made great leaps forward rapidly in the field of drug repositioning. However, there is no relevant review to summarize the transformations and development process of models and their data in the field of drug repositioning. Among all the computational methods, network‐based methods play an extraordinary role. In view of these circumstances, understanding and comparing existing network‐based computational methods applied in drug repositioning will help us recognize the cutting‐edge technologies and offer valuable information for relevant researchers. Therefore, in this review, we present an interpretation of the series of important network‐based methods applied in drug repositioning, together with their comparisons and development process.
- 12 May 2021
- Published by Springer Nature in Applied Intelligence
- Vol. 52 (1) , 846-857
KG-DTI: a knowledge graph based deep learning method for drug-target interaction predictions and Alzheimer’s disease drug repositions
- 12 May 2021
- Published by Springer Nature in Applied Intelligence
- Vol. 52 (1) , 846-857
KG-DTI: a knowledge graph based deep learning method for drug-target interaction predictions and Alzheimer’s disease drug repositions
- Open Access
- 19 February 2021
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 11
SE-OnionNet: A Convolution Neural Network for Protein–Ligand Binding Affinity Prediction
Deep learning methods, which can predict the binding affinity of a drug–target protein interaction, reduce the time and cost of drug discovery. In this study, we propose a novel deep convolutional neural network called SE-OnionNet, with two squeeze-and-excitation (SE) modules, to computationally predict the binding affinity of a protein–ligand complex. The OnionNet is used to extract a feature map from the three-dimensional structure of a protein–drug molecular complex. The SE module is added to the second and third convolutional layers to improve the non-linear expression of the network to improve model performance. Three different optimizers, stochastic gradient descent (SGD), Adam, and Adagrad, were also used to improve the performance of the model. A majority of protein–molecule complexes were used for training, and the comparative assessment of scoring functions (CASF-2016) was used as the benchmark. Experimental results show that our model performs better than OnionNet, Pafnucy, and AutoDock Vina. Finally, we chose the macrophage migration inhibitor factor (PDB ID: 6cbg) to test the stability and robustness of the model. We found that the prediction results were not affected by the docking position, and thus, our model is of acceptable robustness.
- 19 February 2021
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 11
Open AccessSE-OnionNet: A Convolution Neural Network for Protein–Ligand Binding Affinity Prediction
Deep learning methods, which can predict the binding affinity of a drug–target protein interaction, reduce the time and cost of drug discovery. In this study, we propose a novel deep convolutional neural network called SE-OnionNet, with two squeeze-and-excitation (SE) modules, to computationally predict the binding affinity of a protein–ligand complex. The OnionNet is used to extract a feature map from the three-dimensional structure of a protein–drug molecular complex. The SE module is added to the second and third convolutional layers to improve the non-linear expression of the network to improve model performance. Three different optimizers, stochastic gradient descent (SGD), Adam, and Adagrad, were also used to improve the performance of the model. A majority of protein–molecule complexes were used for training, and the comparative assessment of scoring functions (CASF-2016) was used as the benchmark. Experimental results show that our model performs better than OnionNet, Pafnucy, and AutoDock Vina. Finally, we chose the macrophage migration inhibitor factor (PDB ID: 6cbg) to test the stability and robustness of the model. We found that the prediction results were not affected by the docking position, and thus, our model is of acceptable robustness.
- Open Access
- 15 February 2021
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 12
Repositioning Drugs to the Mitochondrial Fusion Protein 2 by Three-Tunnel Deep Neural Network for Alzheimer's Disease
Alzheimer's disease (AD) is a common neurodegenerative dementia in the elderly. Although there is no effective drug to treat AD, proteins associated with AD have been discovered in related studies. One of the proteins is mitochondrial fusion protein 2 (Mfn2), and its regulation presumably be related to AD. However, there is no specific drug for Mfn2 regulation. In this study, a three-tunnel deep neural network (3-Tunnel DNN) model is constructed and trained on the extended Davis dataset. In the prediction of drug-target binding affinity values, the accuracy of the model is up to 88.82% and the loss value is 0.172. By ranking the binding affinity values of 1,063 approved drugs and small molecular compounds in the DrugBank database, the top 15 drug molecules are recommended by the 3-Tunnel DNN model. After removing molecular weight <200 and topical drugs, a total of 11 drug molecules are selected for literature mining. The results show that six drugs have effect on AD, which are reported in references. Meanwhile, molecular docking experiments are implemented on the 11 drugs. The results show that all of the 11 drug molecules could dock with Mfn2 successfully, and 5 of them have great binding effect.
- 15 February 2021
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 12
Open AccessRepositioning Drugs to the Mitochondrial Fusion Protein 2 by Three-Tunnel Deep Neural Network for Alzheimer's Disease
Alzheimer's disease (AD) is a common neurodegenerative dementia in the elderly. Although there is no effective drug to treat AD, proteins associated with AD have been discovered in related studies. One of the proteins is mitochondrial fusion protein 2 (Mfn2), and its regulation presumably be related to AD. However, there is no specific drug for Mfn2 regulation. In this study, a three-tunnel deep neural network (3-Tunnel DNN) model is constructed and trained on the extended Davis dataset. In the prediction of drug-target binding affinity values, the accuracy of the model is up to 88.82% and the loss value is 0.172. By ranking the binding affinity values of 1,063 approved drugs and small molecular compounds in the DrugBank database, the top 15 drug molecules are recommended by the 3-Tunnel DNN model. After removing molecular weight <200 and topical drugs, a total of 11 drug molecules are selected for literature mining. The results show that six drugs have effect on AD, which are reported in references. Meanwhile, molecular docking experiments are implemented on the 11 drugs. The results show that all of the 11 drug molecules could dock with Mfn2 successfully, and 5 of them have great binding effect.